David Mitchell
General Counsel at VERASTEM, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dan Paterson | M | 63 | 13 years | |
| Daniel Calkins | M | 37 | 6 years | |
| Michael Kauffman | M | 60 | 12 years | |
| Brian Stuglik | M | 64 | 7 years | |
| Eric Rowinsky | M | 67 | 7 years | |
| John Johnson | M | 66 | 4 years | |
| Susan Alexander | F | 67 | 21 years | |
| Cathy Carew | F | - | - | |
| Paul Bunn | M | 79 | 3 years | |
| Anil Kapur | M | 54 | 2 years | |
| Michelle Robertson | F | 57 | 3 years | |
| Robert Gagnon | M | 49 | 2 years | |
| Hagop Youssoufian | M | 67 | 7 years | |
| Jonathan Pachter | M | 66 | 13 years | |
| Karin Tollefson | M | 57 | 1 years | |
| Michael Crowther | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William Young | M | 79 | 11 years | |
| Elaine Jones | M | 69 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 5 years |
| Robert A. Hamm | M | 72 | 7 years | |
| Craig Eric Schneier | M | 76 | 8 years | |
| Paul Clancy | M | 62 | 16 years | |
| Gilmore O’Neill | M | 59 | 15 years | |
| Shelley McCloskey | F | 64 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 3 years |
| Sylvie Grégoire | M | 62 | 8 years | |
| Barbara Troupin | M | 56 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 years |
| Sean Nolan | M | 56 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 4 years |
| Michael Kelly | M | 67 | 2 years | |
| Evan M. Beckman | M | - | - | |
| Andrew Hirsch | M | 53 | 9 years | |
| Thomas F. Keller | M | 92 | - | |
| Eric W. Kimble | M | 58 | 5 years | |
| John Cox | M | 61 | 14 years | |
| Allen Kamer | M | 53 | 3 years | |
| John Leonard | M | 77 | 15 years | |
| Michael Rudolf | M | - | - | |
| Michael LaBarre | M | 60 | 3 years | |
| William Sibold | M | - | - | |
| Maiken Keson-Brookes | F | 52 | 5 years | |
| James Kelly | M | 58 | 5 years | |
| Lisa Buffington | F | - | 4 years | |
| Timothy D. Hunt | M | - | 9 years | |
| Michael Panzara | M | 57 | 8 years | |
| Ben Harshbarger | M | 55 | 5 years | |
| Johanna Friedl-Naderer | F | 56 | 21 years | |
| Abbey Jenkins | F | - |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | - |
| Richard Brudnick | M | 67 | 15 years | |
| Michael Cloonan | M | 53 | 14 years | |
| Paula Cobb | F | 51 | 13 years | |
| Barry Ticho | M | 64 | 13 years | |
| Alexey A. Lugovskoy | M | 51 | 9 years | |
| Pratik Multani | M | 57 | 5 years | |
| Bonne Adams | F | 47 | 2 years | |
| Patrick Volkert Vink | M | 60 | 2 years | |
| Michael Bonney | M | 65 | 6 years | |
| Edward Hu | M | 61 | 2 years | |
| Douglas A. Abel | M | 62 | 4 years | |
| Carol Gallagher | M | 59 | 1 years | |
| Michael D. Kowolenko | M | 68 | - | |
| Arturo Molina | M | 65 | 4 years | |
| Ted Llana | M | 60 | 7 years | |
| Lawrence C. Best | M | 75 | - | |
| William R. Rohn | M | 80 | 2 years | |
| John Dunn | M | 72 | 9 years | |
| Peter Kellogg | M | 67 | 4 years | |
| Hans-Peter Hasler | M | 68 | 8 years | |
| Steven Perrin | M | 59 | 5 years | |
| Elan Ezickson | M | 60 | 9 years | |
| Stephen Shrewsbury | M | 67 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 3 years |
| Nancy Simonian | M | 63 | 6 years | |
| David Hallal | M | 57 | 2 years | |
| Paul Aldridge | M | - | - | |
| Jennifer A. Spinella | F | - | - | |
| Paul A. Brennan | M | - |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 2 years |
| James Dentzer | M | 57 | 3 years | |
| Katherine J. Turner | M | 70 | 4 years | |
| Robert Perez | M | 59 | 8 years | |
| Melissa Morandi | F | 59 | 2 years | |
| Jason Robertson | M | - |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 70 | 89.74% |
| Canada | 8 | 10.26% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Mitchell
- Personal Network
